The identification of novel selenium compounds that have good chemopreventive activity and low toxicity is of great potential benefit. We have uncovered important determinants of these effects that resulted in the discovery of a new class of chemopreventive compounds. These compounds provide a means for relatively straightforward exploration of mechanisms of chemopreventive action compared to other organoselenium compounds that show less metabolic stability. It is proposed that lipophilic derivatives of selenium and sulfur are produced through known biochemical reactions to create similar types of chemopreventive compounds. The purpose of this study is to synthesize novel organoselenium compounds for testing, study their metabolism in the whole animal to correlate critical metabolites with chemopreventive activity, and define the biochemical origin of critical metabolites in cell-free systems. The long-term goal is to develop improved chemopreventive compounds of low toxicity for possible long-term use in humans. This work will lead to a better understanding of chemopreventive mechanisms of selenium. It also provides an important conceptual advance in understanding how chemopreventive activity can be developed and enhanced during the metabolism of selenium or sulfur in plants and animals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA045164-12
Application #
6300292
Study Section
Project Start
2000-03-01
Project End
2002-02-28
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
12
Fiscal Year
2000
Total Cost
$179,941
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Dong, Yan; Ganther, Howard E; Stewart, Carleton et al. (2002) Identification of molecular targets associated with selenium-induced growth inhibition in human breast cells using cDNA microarrays. Cancer Res 62:708-14
Zhu, Zongjian; Jiang, Weiqin; Ganther, Howard E et al. (2002) Mechanisms of cell cycle arrest by methylseleninic acid. Cancer Res 62:156-64
Jiang, W; Zhu, Z; Ganther, H E et al. (2001) Molecular mechanisms associated with Se-allylselenocysteine regulation of cell proliferation and apoptosis. Cancer Lett 162:167-73
Unni, E; Singh, U; Ganther, H E et al. (2001) Se-methylselenocysteine activates caspase-3 in mouse mammary epithelial tumor cells in vitro. Biofactors 14:169-77
Ganther, H E (2001) Selenium metabolism and mechanisms of cancer prevention. Adv Exp Med Biol 492:119-30
Medina, D; Thompson, H; Ganther, H et al. (2001) Se-methylselenocysteine: a new compound for chemoprevention of breast cancer. Nutr Cancer 40:12-7
Ganther, H E (2001) Selenotyrosine and related phenylalanine derivatives. Bioorg Med Chem 9:1459-66
Block, E; Birringer, M; Jiang, W et al. (2001) Allium chemistry: synthesis, natural occurrence, biological activity, and chemistry of Se-alk(en)ylselenocysteines and their gamma-glutamyl derivatives and oxidation products. J Agric Food Chem 49:458-70
Dong, Y; Lisk, D; Block, E et al. (2001) Characterization of the biological activity of gamma-glutamyl-Se-methylselenocysteine: a novel, naturally occurring anticancer agent from garlic. Cancer Res 61:2923-8
Ganther, H; Ip, C (2001) Thioredoxin reductase activity in rat liver is not affected by supranutritional levels of monomethylated selenium in vivo and is inhibited only by high levels of selenium in vitro. J Nutr 131:301-4

Showing the most recent 10 out of 62 publications